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Abstract: Background Treatment with immune checkpoint and BRAF/MEK inhibitors has significantly
improved the survival of patients with advanced cutaneous melanoma and other metastatic malignancies.
Therapy-related uveitis is a rare ocular adverse event, which may potentially lead to legal blindness. The
epidemiology of treatment-related uveitis is currently insufficiently known. Patients and methods In this
cohort study, we asked whether exposure to either immune checkpoint or BRAF/MEK inhibitors was
associated with a higher risk of developing uveitis compared with the general population. Based on a
Bayesian framework, we estimated the probability of developing uveitis with a right-censored, exponential
survival model using data from the Zurich Melanoma Registry. The registry included all adult patients
treated for advanced cutaneous melanoma between January 2008 and December 2018 at the University
Hospital of Zurich, Switzerland. Results In total, 304 patients (64%) were treated with immune checkpoint
and 186 patients (38%) with BRAF/MEK inhibitors. Median follow-up time was 74 days (interquartile
range: 57–233 days). Eleven patients developed uveitis and 30 patients died. We estimated the probability
of developing uveitis per year in the general population as 0.05% (95% credibility interval [CrI]: 0.02%–
0.1%). Corresponding posterior probabilities of treatment-related uveitis were 3.48% (95% CrI: 0.93%–
7.49%) and 5.04% (95% CrI: 2.07%–9.19%) for immune checkpoint or BRAF/MEK inhibitors (posterior
probability for difference: 76%). Conclusions Immune checkpoint and particularly BRAF/MEK inhibitor
therapies are associated with an increase in the risk of developing uveitis. Treatment-related uveitis is
not associated with systemic adverse events of immune checkpoint or BRAF/MEK inhibitors.
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Abstract Background: Treatment with immune checkpoint and BRAF/MEK inhibitors has
significantly improved the survival of patients with advanced cutaneous melanoma and other
metastatic malignancies. Therapy-related uveitis is a rare ocular adverse event, which may
potentially lead to legal blindness. The epidemiology of treatment-related uveitis is currently
insufficiently known.
Patients and methods: In this cohort study, we asked whether exposure to either immune
checkpoint or BRAF/MEK inhibitors was associated with a higher risk of developing uveitis
compared with the general population. Based on a Bayesian framework, we estimated the
probability of developing uveitis with a right-censored, exponential survival model using data
from the Zurich Melanoma Registry. The registry included all adult patients treated for
advanced cutaneous melanoma between January 2008 and December 2018 at the University
Hospital of Zurich, Switzerland.
Results: In total, 304 patients (64%) were treated with immune checkpoint and 186 patients
(38%) with BRAF/MEK inhibitors. Median follow-up time was 74 days (interquartile range:
57e233 days). Eleven patients developed uveitis and 30 patients died. We estimated the prob-
ability of developing uveitis per year in the general population as 0.05% (95% credibility inter-
val [CrI]: 0.02%e0.1%). Corresponding posterior probabilities of treatment-related uveitis
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were 3.48% (95% CrI: 0.93%e7.49%) and 5.04% (95% CrI: 2.07%e9.19%) for immune check-
point or BRAF/MEK inhibitors (posterior probability for difference: 76%).
Conclusions: Immune checkpoint and particularly BRAF/MEK inhibitor therapies are associ-
ated with an increase in the risk of developing uveitis. Treatment-related uveitis is not associ-
ated with systemic adverse events of immune checkpoint or BRAF/MEK inhibitors.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Treatment with immune checkpoint and BRAF/MEK
inhibitors has significantly improved the survival of
patients with advanced cutaneous melanoma [1e7].
These treatments have also been associated with a wide
spectrum of autoimmune or inflammatory side-effects
[8e11]. Some of the side-effects, such as cardiac or
neurological events, occur very rarely but may poten-
tially lead to irreversible organ damage [12]. Various
studies have reported unspecific ocular adverse events
occurring in about 1e4% of patients during treatment
with immune checkpoint inhibitors [11,13e17] and in
25e100% of the patients treated with BRAF/MEK in-
hibitors [18e20]. Most of these ocular adverse effects,
such as dry eye, ocular and orbital inflammations,
neuro-ophthalmic disorders, or serous retinopathy, are
reversible [21]. However, treatment-related uveitisda
rare but severe form of non-infectious inflammation of
the uveal tractdcan lead to irreversible visual
impairment.
At present, only sparse datadmainly case
reportsdwere describing uveitis as a potentially
treatment-related side-effect [17,22e25]. Clinical trials,
investigating treatment efficacy of immune checkpoint
and BRAF/MEK inhibitors, have limited power to
detect rare but potentially serious adverse events; hence,
rare adverse eventsdsuch as uveitisdwere systemati-
cally underreported [26]. The epidemiology of therapy-
associated uveitis is therefore currently not known.
The primary objective of this study was to investigate
if the occurrence of uveitis under treatment is more
frequent than in a general population of patients
without treatment for cutaneous melanoma. In second-
ary analyses, we investigated if the risk of uveitis differs
between treatments, and if the development of uveitis
was associated with systemic adverse effects during
treatment with immune checkpoint or BRAF/MEK in-
hibitor therapy.
2. Methods
2.1. Study design and population
Data were obtained from the cancer registry of the
Comprehensive Cancer Center Zurich (CCCZ), which
includes all adult patients with advanced cutaneous
melanoma treated in the University Hospital of Zurich,
Switzerland, since January 2008. We included all pa-
tients who had their first-line therapy of either immune
checkpoint (anti-CTLA-4 or anti-PD-1 inhibitor) or
BRAF/MEK inhibitors between January 2008 and
December 2018. Patients with a history of uveitis,
experimental treatment combinations (bevacizumab,
sorafenib and selumetinib), or triple combinations of
immune checkpoint and BRAF/MEK inhibitors were
excluded. The analysis of the registry data was approved
by the local ethics committee (KEK-ZH 2014-0193).
2.2. Outcome and independent variables
The primary outcome was the risk of non-infectious
uveitis per year. We systematically searched all charts of
the patients for documented ophthalmic consultations.
We considered a patient having a non-infectious uveitis
if the diagnosis was confirmed based on SUN criteria
[27] and an ophthalmological consult in the chart has
documented that possible infectious aetiologies have
been ruled out. Characteristics of the patients were
collected by an independent research registry team. The
recorded variables included age, gender, melanoma
stage, genetic pattern of melanoma, therapy with ste-
roids, and history of uveitis, rheumatoid or infectious
diseases. We considered exposure to all types of anti-
CTLA-4 (ipilimumab) and/or anti-PD-1 (pem-
brolizumab, nivolumab) as immune checkpoint inhibi-
tor treatment. BRAF/MEK inhibitor therapy was
defined as exposure to either BRAF, MEK or BRAF/
MEK inhibitor treatment. The time origin of analyses
was defined as the start date of treatment. The follow-up
period ended either at the occurrence of uveitis, at death,
at the end of therapy (disease-progression, stop of drug
intake, end of study), or at loss to follow-up.
2.3. Statistical analysis
Patient characteristics were described with proportions
for categorical and mean (standard deviation) or median
(interquartile range [IQR]) for continuous variables.
Cumulative probability curves were computed and
illustrated for the following states: occurrence of uveitis,
death, or being alive. Baseline characteristics were
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stratified by type of exposure to either immune check-
point or BRAF/MEK inhibitors. No assumptions were
made for missing data.
We used a Bayesian framework to answer the pri-
mary research question. A gamma prior distribution
for the cumulative incidence of uveitis at 1 year in the
general population was defined with a shape of 50/8
and a rate of 1/8 per 100,000 persons. The corre-
sponding mean was defined to reflect a cumulative
incidence of 50 per 100,000 person-years [28]. Markov
chain Monte Carlo modelling (with 3 chains, 10,000
iterations burn-in and 50,000 saved iterations per
chain) was used to derive a right-censored, exponential
survival model including treatment with either immune
checkpoint or BRAF/MEK inhibitor therapy as pre-
dictor variables. The model assumes a constant hazard
of developing uveitis. Based on this model, we esti-
mated the mean probability of uveitis with 95% credible
intervals (CrIs) for patients treated with immune
checkpoint or BRAF/MEK inhibitor therapy from the
posterior distribution.
To answer the second research question, we calcu-
lated the hazard ratio to describe the difference in the
hazard of developing uveitis between the two treat-
ments. Furthermore, mean probabilities to exceed pre-
specified thresholds of the hazard ratio were computed.
Three sensitivity analyses were performed. First, we
restricted the data set to patients without history of
rheumatological diseases and without steroid treatment.
Patients with rheumatological diseases potentially have
an increased baseline risk of developing uveitis, whereas
steroid treatment will reduce the risk of uveitis. Second,
we used a Bayesian Poisson mixture model, instead of a
survival model, to confirm the robustness of our esti-
mates for different model assumptions. Third, we
repeated the analysis with a Bayesian Poisson mixture
model adjusting for differences in the number of eye
examinations between groups using stabilised inverse
probability weights. This analysis would allow to
identify detection bias due to systematic differences in
terms of eye examinations between the two exposure
groups. Model performance was evaluated by
comparing the number of predicted cases with uveitis to
observed cases with uveitis before censoring. The Gel-
maneRubin statistic was used to assess model
convergence.
We used 2  2 cross tabulation and the McNemar
test to assess if systemic adverse effects were pairwise
associated with the development of uveitis during
treatment with immune checkpoint or BRAF/MEK in-
hibitor therapy. We considered all treatment-related
adverse effects leading to hospitalisation as systemic
adverse effect.
All analyses were performed in R software, version
3.5.3 (www.r-project.org), and JAGS (4.3.0) using the
‘rjags’ package [29] to run JAGS [30]. Details and the
code of the analysis are available at EJC Supplement.
3. Results
3.1. Patients characteristics
The registry included 612 patients, of which 122 patients
did not meet inclusion criteria (eFig. 1, available at EJC
Supplement). A total of 490 patients were included in the
final analysis. 304 patients (62%) were treated with im-
mune checkpoint inhibitors and 186 patients (38%) with
BRAF/MEK inhibitors. Eighty-two patients (16.7%) of
our cohort had an ophthalmic examination. Seventy-
four of these 82 patients had pre-planned eye examina-
tions mandated by a clinical trial protocol. More
ophthalmological examinations were reported in pa-
tients who were treated with BRAF/MEK compared to
immune checkpoint inhibitors (68 versus 14 examina-
tions, 36.6% versus 14.6% per group). A total of 11
patients developed uveitis (4 of 304 patients treated with
immune checkpoint inhibitors and 7 of 186 patients
treated with BRAF/MEK inhibitors), while 30 patients
died during the treatment (Fig. 1). Median (IQR) time
of follow-up for patients with immune checkpoint in-
hibitor treatment was 63 days (42e94 days) and for
patients with BRAF/MEK inhibitor treatment was 172
days (94.50e332 days). Thirty-one patients (6%) had a
documented history of a rheumatological disease, and
51 patients (10.4%) had a documented history of treat-
ment with steroids at baseline. During follow-up,
treatment with steroids was recorded in 149 patients
(30%). The steroids were newly prescribed in 113 of 149
patients during follow-up, while a pre-existing therapy
with steroids was continued in 36 patients. Sixty-two of
the 149 patients treated with steroids during follow-up
(42%) had brain metastasis. Eighty-two of the 149 pa-
tients treated with steroids during follow-up (55%) had
systemic adverse effects of the therapy. Details of the
patient’s baseline characteristics are illustrated in
Table 1.
3.2. The risk of uveitis during treatment compared to the
general population
Based on previous work describing the incidence of
uveitis between 17 and 52 cases per 100,000 person-
years (Table 2), we assumed a more conservative prior
probability of 0.05% (95% CrI: 0.02%e0.1%)
regarding the risk of developing uveitis in the general
population per year. Compared with the general
population, patients with cutaneous melanoma who
received immune checkpoint or BRAF/MEK inhibitor
therapy had an 83-fold (95% CrI: 16e236) or 120-fold
(95% CrI: 34e313) increased risk of developing uve-
itis. In absolute values, the probabilities of developing
uveitis during a 1-year treatment were 3.48% (95%
CrI: 0.93%e7.49%) and 5.04% (95% CrI: 2.07%e
9.19%) for immune checkpoint or BRAF/MEK
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inhibitor therapy, respectively. Systemic adverse
events were not associated with the development of
uveitis (McNemar’s chi-squared Z 120.89, df Z 1, p-
value <0.001) (eTable 1).
In a sensitivity analysis, we excluded patients with a
previous history of rheumatological disease or therapy
with steroids. In this subgroup analysis, the probabilities
of developing uveitis were 1.40% (95% CrI: 0.06%e
Fig. 1. Outcome in relation to treatment regimen for advanced cutaneous melanoma. Cumulative probability curves stratified by treatment
with either immune checkpoint or BRAF/MEK inhibitors are illustrated for the following states: being alive, death or occurrence of uveitis
(n Z 490). BRAF, B-RAF proto-oncogene; MEK, mitogen-activated protein kinase.
Table 1
Baseline characteristics and outcomes of patients with advanced cutaneous melanoma.
Characteristic All patients Immune checkpoint inhibitors BRAF/MEK inhibitors
N 490 304 186
Age, y 62 [50, 72] 64 [52, 72] 58 [49, 71]
Women, no. (%) 189 (38.6) 116 (38.2) 73 (39.2)
Rheumatological disease, no (%) 31 (6.3) 21 (6.9) 10 (5.4)
Therapy with steroids, no (%) 51 (10.4) 27 (8.9) 24 (12.9)
Melanoma disease
BRAFþ, no. (%) 254 (51.7) 89 (29.3) 165 (88.7)
NRASþ, no (%) 85 (17.3) 74 (24.3) 12 (6.5)
BRAF-/NRAS-, or not specified (%) 152 (31.0) 141 (46.4) 11 (5.9)
Metastatic sites involved  2, no. (%) 304 (62.0) 213 (70.1) 91 (48.9)
Brain metastasis, no. (%) 103 (21.0) 43 (14.1) 60 (32.3)
Immune checkpoint inhibitors
Anti-CTLA-4 235 (48.0) 235 (77.3) e
Anti-PD1 98 (20.0) 98 (32.2) e
Anti-CTLA-4/PD-1 29 (5.9) 29 (9.5) e
BRAF/MEK inhibitors
BRAF 109 (22.2) e 109 (58.6)
MEK 21 (4.3) e 21 (11.3)
BRAF/MEK 56 (11.4) e 56 (30.1)
Ophthalmological examination, no. (%) 82 (16.7) 14 (4.6) 68 (36.6)
Outcomes
Alive, no. (%) 449 (91.6) 292 (96.1) 157 (84.4)
Uveitis, no. (%) 11 (2.2) 4 (1.3) 7 (3.8)
Death, no. (%) 30 (6.1) 8 (2.6) 22 (11.8)
Follow-up time, d 74 [57,233] 63.00 [42, 94] 172 [95, 332]
We considered exposure to all types of anti-CTLA-4 (ipilimumab) or anti-PD1 (pembrolizumab, nivolumab) as immune checkpoint inhibitor
treatment. BRAF/MEK inhibitor therapy was defined as exposure to either BRAF, MEK or BRAF/MEK combination inhibitor treatment.
MEK, Mitogen-activated protein kinase; BRAF, B-RAF proto-oncogene.
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5.06%) and 2.16% (95% CrI: 0.27%e6.00%) for immune
checkpoint or BRAF/MEK inhibitors. The robustness
of our estimates was confirmed in an analysis using a
Bayesian mixture model (see supplementary information
available at EJC Supplement).
3.3. Difference in risks of uveitis between immune
checkpoint and BRAF/MEK inhibitor therapy
Patients under treatment with BRAF/MEK inhibitors
had a two-fold higher hazard of developing uveitis
(hazard ratio: 2.00; 95% CrI: 0.43e6.32). The proba-
bility that patients with BRAF/MEK inhibitor therapy
have a higher risk of developing uveitis was 75.9%
(eTable 2 available at EJC Supplement). The probability
for an increase of >40% in the hazard of developing
uveitis was 57.5%. Similar results were found in a
sensitivity analysis using inverse probability weighting
to adjust for different number of eye exams between
exposure groups (eTable 3 available at EJC Supple-
ment). All four cases of uveitis (1.3%) in patients treated
with immune checkpoint inhibitors were observed under
treatment with anti-CTLA-4 inhibitors. No uveitis was
detected in patients treated with anti-PD-1 inhibitors.
3.4. Characteristics of treatment-related uveitis
In eight of 11 patients with uveitis, eye symptoms led to
a referral to the ophthalmologist. Three uveitis cases
were diagnosed during a scheduled ophthalmic exami-
nation mandated as part of a clinical trial protocol. Two
of the three patients were completely asymptomatic.
Most patients with uveitis presented with a bilateral,
anterior fibrinous uveitis with small keratic precipitates
and a tendency to progress with posterior synechiae and
vitreous spill over. Clinical findings (slit lamp and bio-
microscopy) were similar in patients treated with im-
mune checkpoint and BRAF/MEK inhibitor therapy.
Recurrence of uveitis was frequent, and complica-
tions requiring systemic steroids in 4/11 included mac-
ular oedema, papilloedema, elevated intraocular
pressure, late formation of cataract, or development of
epiretinal membranes (Fig. 2). Persistent reduction of
visual acuity was observed in five of 11 patients. No one
had to discontinue the oncological therapy. Additional
details are presented in Table 3.
4. Discussion
Immune checkpoint and particularly BRAF/MEK in-
hibitor therapy were associated with a significant in-
crease in the risk of uveitis compared with the general
population. While in our cohort, the mean relative in-
crease in the risk of uveitis was between 80- and 120-
fold, the absolute risk can still be considered relatively
low. The mean probability of developing uveitis during
1 year of treatment was between 3% and 5%. This must
be interpreted in the context of a life-saving cancer
therapy, which prolongs the overall survival from
advanced cutaneous melanoma and other metastatic
malignancies.
Our results are in good agreement with previous work
on treatment-related ocular toxicities. Choe et al. re-
ported the incidence of uveitis at 4.0% (95% CI: 2.6%e
6.0%) during treatment of 568 patients with Vemur-
afenib for a duration ranging from 7 to 550 days [18].
Bitton et al. estimated the probability of developing a
moderate to severe ocular adverse event during a 1-year
treatment with anti-PD-(L)1 at 0.8% [15]. Both studies,
however, did not describe if patients were treated with
either immune checkpoint or BRAF/MEK inhibitors
before enrollment. Alves et al. did a systematic review
and meta-analysis of patients treated with MEK in-
hibitors but did not find an increased risk of uveitis [20].
Previous case reports described various clinical patterns
of treatment-related uveitis, including the occurrence of
extraocular manifestations resembling the
VogteKoyanagieHarada disease [22,23,25]. In our
cohort, however, the development of uveitis was not
associated with other systemic adverse events or extra-
ocular toxicities.
As a strength of our work, we quantified the risk of
treatment-related uveitis compared to the risk of the
general population and demonstrated that the risk of
uveitis is higher during first-line treatment with BRAF/
MEK compared with immune checkpoint inhibitors.
Interestingly, all cases of uveitis in patients treated with
immune checkpoint inhibitors were observed under
treatment with anti-CTLA-4 inhibitors (ipilimumab),
whereas no uveitis was detected in patients solely treated
with anti-PD-1 inhibitors. Our research questions could
not have been answered with a traditional frequentist
statistics framework. The Bayesian approach facilitated
reliable estimations even with a very small number of
Table 2
Reported incidence of uveitis in different population-based studies.
Author Region Population size Incidence of uveitis
(per 100 000 person-years)
Acharya 2013 [33] California and Hawaii, United States 217,061 24.9
Gritz 2004 [28] California, United States 731,895 52
Saari 1995 [34] Finland 459,515 22.6
Tran 1994 [35] Switzerland 558 17.5
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events and a limited sample size [26,31]. We used two
different Bayesian modelling strategies to estimate the
risk of uveitis per year and found similar estimates in the
exponential survival model and in the Poisson mixture
model (see supplementary information). Nevertheless,
our study has several limitations. First, our analysis
does not definitely prove causality. We cannot rule out
that common genetic factors or immunologic phenom-
ena related to the melanoma influence the risk for
developing uveitis. As numerous other treatments be-
sides immune checkpoint and BRAF/MEK inhibitors
are known to promote the development of uveitis [32],
estimation of the uveitis risk in the melanoma popula-
tion is difficult.
Second, our analysis might be influenced by residual
confounding. We did a sensitivity analysis restricted to
patients without rheumatologic diseases and without
steroid therapy to estimate the influence of confounding
factors. Furthermore, information bias was minimised
by manually verifying each ophthalmologic consult of
the patients in the registry.
Third, not all patients underwent regularly sched-
uled ophthalmologic controls during follow-up, which
includes the possibility that cases of very mild,
asymptomatic uveitis could have been missed.
Furthermore, differences in the number of eye exami-
nations between exposure groups could have intro-
duced potential detection bias. However, significant
under-detection of uveitis is very unlikely in a cohort of
melanoma patients who were closely monitored
because of their melanoma treatment. The estimates of
our sensitivity analysis using inverse probability
weighting to adjust for differences in the number of eye
examinations between exposure groups were compara-
ble to the estimates of the main analysis. In addition, a
failure to detect mild, asymptomatic cases of uveitis
would lead to more conservative estimates in our
analysis.
Fig. 2. Epiretinal membrane on treatment with combined BRAF and MEK inhibition (encorafenib/binimetinib), a late complication of re-
lapsing uveitis. Multicolour scanning laser ophthalmoscopy and linear optical coherence tomography scan of the right eye shows the
widespread yellowish epiretinal membrane, delineated as a highly reflective contour on the inner retinal surface. The central retina is
stretched with abnormal foveal depression (A). In contrast, the subfoveal neuroretinal detachment (yellow arrow) is a toxic side-effect
caused by the intake of an MEK inhibitor 2 h before the examination. This is emphasised by mild oedema of the outer layers in the
left eye (B). Visual acuity on the right side was 20/25 and on the left side was 20/16. (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this article.)
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Table 3












Location Onset/Duration/Course Grade/Findings Outcome of
melanoma
1 33 (M) Anti-CTLA4 52 Blurred vision,
floaters myopisation
(3)
Colitis Anterior þ intermediate Insidious, persistent,
chronic
3þ/3þ; Posterior synechiae,
elevated io pressure, vitreous haze,
floaters, retinal þ papilloedema
PD
2 43 (M) BRAFi þ
MEKi






2þ/1þ; Posterior synechiae, later
epiretinal membrane
PR
3 55 (M) Anti-CTLA4 þ Anti-
PD1




2þ/2þ; Vitreous haze þ cells
cystoid retinal oedema, epiretinal
membrane
SD
4 82 (F) BRAFi þ MEKi 345 Red eye, irritation
(2)
None Anterior þ intermediate Sudden, limited, acute 4þ/4þ, Hypotonia, serous retinal
detachment
PD
5 77 (M) BRAFi þ MEKi 196 No symptoms (1) None Anterior þ intermediate þ
optic nerve
Insidious, limited, acute 2þ/2þ; Posterior synechiae;
vitreous haze, retinal bleeding,
papilloedema
PD
6 58 (M) BRAFi 141 Blurred vision, red
eye (2)
None Anterior þ intermediate Insidious, persistent,
recurrent
2þ/2þ; Posterior synechiae PD
7 50 (F) BRAFi 47 Blurred vision (2) None Anterior þ intermediate þ
retina
Sudden, recurrent Posterior synechiae, retinal
vasculitis
PD
8 37 (F) BRAFi þ MEKi 628 Blurred vision (2) None Anterior þ intermediate þ
macula
Sudden, chronic 2þ/2þ; Posterior synechiae;
macular oedema
PD
9 73 (F) Anti-CTLA4 þ Anti-
PD1
62 ns None Anterior, bilateral ns Posterior synechiae, uveal
melanoma left
PD
10 73 (M) BRAFi 60 ns None Anterior ns ns PD
11 43 (M) Anti-CTLA4 45 Blurred vision (3) CRS Anterior þ intermediate þ
optic nerve
Sudden, persistent 2þ/2, Elevated io pressure,
papilloedema
PD
The severity of symptoms was graded using the classification of the CTCAEv4. The type and severity of uveitis was graded according to SUN criteria [27].
CRS, Cytokine release syndrome; CR, complete response; SD, stable disease; PR, partial response; PD, progressive disease; ns, not specified; CTCAE, Common Terminology Criteria for Adverse
















































Fourth, our analysis does not answer the question
whether a triple combination therapy (BRAF/MEK/
PD1 inhibitors) additionally increases the risk of uveitis.
Our registry only comprised three patients on triple
therapy. Reliable estimation of an interaction term was
therefore not feasible.
Finally, uveitis is considered an orphan disease
showing large geographic and ethnic differences.
Therefore, the prior gamma distribution with a mean
incidence rate of 50 per 100,000 person-years might be at
the upper limit of the true incidence rate in Switzerland
(Table 2). Also, the duration of follow-up in our study is
relatively short for the detection of uveitis. Both factors
could have resulted in more conservative estimates of
our analysis.
The novel treatment strategies have resulted in a
prolonged overall survival of cancer patients. Further-
more, combination or sequenced therapies are currently
investigated, which will likely result in an increased rate
of treatment-related uveitis and in more late complica-
tions. Further research is needed to investigate whether
uveitis represents a surrogate marker for mortality. Pa-
tients must be informed about the risk of uveitis before
initiation of therapy. Considering the significantly
increased risk of developing treatment-related uveitis
during immune checkpoint and BRAF/MEK inhibitor
therapy, an immediate referral and interdisciplinary
approach is required in patients with eye symptoms to
allow early intervention and prevention of serious
functional loss.
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Ultrasun, L’Oréal, Merck Sharp & Dohme, Bristol-
Myers Squibb (BMS) and Pierre Fabre outside of the
submitted work. RD has intermittent, project focused
consulting and/or advisory relationships with Novartis,
Merck Sharp & Dohme (MSD), Bristol-Myers Squibb
(BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun
Pharma, Sanofi outside the submitted work. MU is
supported by a Vanier Canada Graduate Scholarship
from the Canadian Institutes of Health Research. CE,
NM and UU declared no conflicts of interest.
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2020.11.027.
References
[1] Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA,
Haanen JB, et al. Improved survival with ipilimumab in patients
with metastatic melanoma. N Engl J Med 2010;363:711e23.
[2] Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L,
et al. Pembrolizumab versus ipilimumab for advanced melanoma:
final overall survival results of a multicentre, randomised, open-
label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853e62.
[3] Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P,
Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone
versus ipilimumab alone in advanced melanoma (CheckMate
067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Lancet Oncol 2018;19:1480e92.
[4] Robert C, Karaszewska B, Schachter J, Rutkowski P,
Mackiewicz A, Stroiakovski D, et al. Improved overall survival in
melanoma with combined dabrafenib and trametinib. N Engl J
Med 2015;372:30e9.
[5] Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di
Giacomo AM, et al. Cobimetinib combined with vemurafenib in
advanced BRAF(V600)-mutant melanoma (coBRIM): updated
efficacy results from a randomised, double-blind, phase 3 trial.
Lancet Oncol 2016;17:1248e60.
[6] Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB,
et al. Long-term outcomes in patients with BRAF V600-mutant
metastatic melanoma who received dabrafenib combined with
trametinib. J Clin Oncol 2018;36:667e73.
[7] Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M,
Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib
or encorafenib in patients with BRAF-mutant melanoma (CO-
LUMBUS): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol 2018;19:603e15.
[8] Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor
toxicities in patients with metastatic melanoma. Ther Adv Med
Oncol 2015;7:122e36.
[9] Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J,
et al. Management of toxicities from immunotherapy: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol 2018;29:iv264e6.
[10] Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L,
Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine,
and renal side-effects of anti-PD-1 therapy. Eur J Canc 2016;60:
190e209.
[11] Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S,
Thomas I, et al. Neurological, respiratory, musculoskeletal, car-
diac and ocular side-effects of anti-PD-1 therapy. Eur J Canc
2016;60:210e25.
[12] Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W,
Weber J, et al. Neurologic serious adverse events associated with
F. Dimitriou et al. / European Journal of Cancer 144 (2021) 215e223222
nivolumab plus ipilimumab or nivolumab alone in advanced
melanoma, including a case series of encephalitis. Oncol 2017;22:
709e18.
[13] Abdel-Rahman O, Oweira H, Petrausch U, Helbling D,
Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in
solid tumor patients treated with immune checkpoint inhibitors: a
systematic review. Expet Rev Anticancer Ther 2017;17:387e94.
[14] Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint
inhibitor immune therapy: systemic indications and ophthalmic
side effects. Retina 2018;38:1063e78.
[15] Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O,
Marabelle A, et al. Prevalence and clinical patterns of ocular
complications associated with anti-PD-1/PD-L1 anticancer
immunotherapy. Am J Ophthalmol 2019;202:109e17.
[16] Sun MM, Levinson RD, Filipowicz A, Anesi S, Kaplan HJ,
Wang W, et al. Uveitis in patients treated with CTLA-4 and PD-1
checkpoint blockade inhibition. Ocul Immunol Inflamm 2019:
1e11.
[17] Kim JM, Materin MA, Sznol M, Kluger HM, Weiss S, Chow J,
et al. Ophthalmic immune-related adverse events of immuno-
therapy: a single-site case series. Ophthalmology 2019;126(7):
1058e62.
[18] Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK.
Ocular toxicity in BRAF mutant cutaneous melanoma patients
treated with vemurafenib. Am J Ophthalmol 2014;158:
831e837.e2.
[19] Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxic-
ities of MEK inhibitors and other targeted therapies. Ann Oncol
2016;27:998e1005.
[20] Alves C, Ribeiro I, Penedones A, Mendes D, Batel Marques F.
Risk of ophthalmic adverse effects in patients treated with MEK
inhibitors: a systematic review and meta-analysis. Ophthalmic Res
2017;57:60e9.
[21] Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL,
Dummer R, Goldinger SM. MEK inhibitor-associated retinop-
athy (MEKAR) in metastatic melanoma: long-term ophthalmic
effects. Eur J Canc 2016;65:130e8.
[22] Fierz FC, Meier F, Chaloupka K, Boni C. Intraocular inflam-
mation associated with new therapies for cutaneous melanoma -
case series and review. Klin Monbl Augenheilkd 2016;233:540e4.
[23] Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A,
Singh A. Checkpoint inhibitor-induced uveitis: a case series.
Graefes Arch Clin Exp Ophthalmol 2017;256:187e91.
[24] Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ,
Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4
blockade in patients with metastatic melanoma: a new cause of
uveitis. J Immunother 2004;27:478e9.
[25] Diamantopoulos PT, Stoungioti S, Anastasopoulou A,
Papaxoinis G, Gogas H. Incomplete Vogt-Koyanagi-Harada
disease following treatment with encorafenib and binimetinib
for metastatic melanoma. Melanoma Res 2018;28:648e51.
[26] Lee CS, Lee AY, Holland GN, Van Gelder RN, Tufail A. Big
data and uveitis. Ophthalmology 2016;123:2273e5.
[27] Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of
uveitis nomenclature working G. Standardization of
uveitis nomenclature for reporting clinical data. Results of the
First international workshop. Am J Ophthalmol 2005;140:
509e16.
[28] Gritz DC, Wong IG. Incidence and prevalence of uveitis in
Northern California; the Northern California epidemiology of
uveitis study. Ophthalmology 2004;111:491e500. discussion.
[29] Plummer M. rjags: Bayesian graphical models using MCMC. R
package version 2013;3.
[30] Plummer MJAGS. A program for analysis of Bayesian graphical
models using Gibbs sampling. In: Proceedings of the 3rd inter-
national workshop on distributed statistical computing; 2003.
Vienna, Austria.
[31] de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI,
Pleyer U, et al. Understanding uveitis: the impact of research on
visual outcomes. Prog Retin Eye Res 2011;30:452e70.
[32] Anquetil C, Salem JE, Lebrun-Vignes B, Touhami S,
Desbois AC, Maalouf G, et al. Evolving spectrum of drug-
induced uveitis at the era of immune checkpoint inhibitors re-
sults from the WHO’s pharmacovigilance database. J Auto-
immun 2020:102454.
[33] Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV,
Vinoya AC, et al. Incidence and prevalence of uveitis: results from
the Pacific Ocular Inflammation Study. JAMA ophthalmology
2013;131:1405e12.
[34] Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H,
Tuominen J, Sillanpaa M. Epidemiology of endogenous uveitis
in south-western Finland. Acta Ophthalmol Scand 1995;73:
345e9.
[35] Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP.
Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm
1994;2:169e76.
F. Dimitriou et al. / European Journal of Cancer 144 (2021) 215e223 223
